-- A high molecular weight mucin associated with pancreatic and colon cancer.
Of the 33 patients in the trial, 6 patients experienced disease stabilization of [greater than or equal to] 4 months, and 1 patient with pancreatic adenocarcinoma who experienced a partial response had a 60% decrease in the tumor marker CA19-9
and carcinoembryonic antigen (CEA), both markers commonly elevated in intestinal or foregut malignancy, were non-specifically elevated at 458 units/mL and 7.
Although serum CA19-9
concentrations are increased in both gastrointestinal and pancreatic cancers, this biomarker shows its highest sensitivity and specificity for the detection of pancreatic cancer in symptomatic patients (approximately 80% and 90%, respectively).
The serum carcinoembryonic antigen (CEA) and CA19-9
levels were normal; CA125 was 71.
The prognostic value of preoperative serum levels of CEA, CA19-9
and CA72-4 in patients with colorectal cancer.
In addition, the results of the NPC-1C biomarker test indicate superior sensitivity as compared to commercially available CEA and CA19-9
assays in pancreatic cancer show excellent clinical accuracy which may be improved further if used in conjunction with established CA19-9
biomarker assays distinguished 92% of cancer cases with inclusion of the classical CA19-9
cancer biomarker and no false positives results among the healthy subjects.
The aim of the proposed here the project is to develop a minimally invasive, plasma-based assay with high specificity on the basis of a metabolic signature in combination with the tumor marker CA19-9
(MxPA PancreasScore) to the exclusion of pancreatic cancer in high-risk groups (chronic pancreatitis, new diagnosed type 2 diabetes and genetic predisposition to pancreatic cancer).
5) Laboratory evaluation and markers for pancreatic malignancy including CA19-9
and carcinoembryonic antigen are typically unremarkable.
Both lesions were positive for CA19-9
, CEA, CK20, and CK7 immunohistochemical stains.